In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with a price target of $90.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors surrounding Palvella Therapeutics’ recent developments. The company has successfully completed enrollment in their Phase 2 TOIVA trial for QTORIN 3.9% rapamycin, targeting patients with cutaneous venous malformations (CVMs). The trial’s design mirrors a previous successful study for microcystic lymphatic malformations, and the upcoming data release in December 2025 is anticipated with optimism.
Slutsky also notes the potential market opportunity for QTORIN 3.9% rapamycin in treating CVMs, which affects a significant patient population in the U.S. Despite the absence of FDA-approved therapies for CVMs, this treatment could address a substantial unmet need. Additionally, the company’s financial health, with over two years of cash runway, supports the Buy rating, as it provides a stable foundation for further development and potential market expansion.
In another report released on September 9, Oppenheimer also initiated coverage with a Buy rating on the stock with a $85.00 price target.